Benzo[c]-2,6-napthyridinone | 143074-57-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: Benzo[c]-2,6-napthyridinone
• 英文别名: 2H-benzo[h][2,6]naphthyridin-1-one
• CAS: 143074-57-1
• 化学式: C₁₂H₈N₂O
• 分子量: 196.208
• InChiKey: NMVBGJUGSXZHEX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  Benzo[c]-2,6-napthyridinone 在 sodium hydride 、 potassium carbonate 、 对甲苯磺酰氯 、 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 36.33h， 生成 2-[(5-methyl-1-tritylimidazol-4-yl)methyl]-6H-benzo[c][2,6]naphthyridine-1,5-dione
  参考文献：
  名称：

  Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones

  摘要：

  Synthesis and pharmacological evaluation of a series of 1,2-dihydro-1-[(5-methyl-1-imidazol-4-yl)methyl]-2-oxopyridine 5-HT3 antagonists are described. The key pharmacophoric elements were defined as a basic nitrogen, a group capable of hydrogen bonding interactions, and an aromatic moiety. 1,2-Dihydro-2-oxopyridine moiety could be a good linking group because of its nicely planar structure. The steric limitations of the aromatic moiety were investigated by X-ray analysis and computer analysis and shown to be optimal when the aromatic moiety was constrained within an arched planar system, which could be successfully replaced by 3-(2-thienyl)-2-oxopyridine function or 6-amino-7-chloro-1-isoquinolinone function without any loss of the activity. Among the synthesized compounds, 42 showed the most potent activity in the inhibition of Bezold-Jarisch reflex in rats. Compounds 44a and 64 were orally active in the protection against cisplatin-induced emesis in dogs or ferrets. Structure-activity relationships are discussed.

  DOI：

  10.1021/jm00096a001

文献信息

• Inhibitors of Checkpoint Kinases
  申请人：Arrington Kenneth L.

  公开号：US20090258852A1

  公开（公告）日：2009-10-15

  The instant invention provides for compounds which comprise benzoisoquinolinones and aza derivatives that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer.

  本发明提供了一种由苯并异喹啉酮和氮杂衍生物组成的化合物，其抑制CHK1活性。本发明还提供了包含这种抑制剂化合物的组合物以及通过将该化合物用于需要治疗癌症的患者来抑制CHK1活性的方法。
• ORGANIC ELECTROLUMINESCENT DEVICE
  申请人：Merck Patent GmbH

  公开号：US20140249308A1

  公开（公告）日：2014-09-04

  The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), to the corresponding compounds, and to a process for the preparation of these compounds.

  本发明涉及电子设备，特别是有机电致发光器件，包括式（1）的化合物，对应的化合物以及制备这些化合物的方法。
• Organic electroluminescent device
  申请人：Merck Patent GmbH

  公开号：US09337430B2

  公开（公告）日：2016-05-10

  The present invention relates to electronic devices, in particular organic electroluminescent devices, comprising compounds of the formula (1), to the corresponding compounds, and to a process for the preparation of these compounds.

  本发明涉及电子设备，尤其是有机电致发光器件，包括公式（1）的化合物，对应的化合物以及制备这些化合物的方法。
• Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones
  作者：Toshiaki Matsui、Tsuneyuki Sugiura、Hisao Nakai、Sadahiko Iguchi、Satoshi Shigeoka、Hideo Takada、Yoshihiko Odagaki、Yuhki Nagao、Yasuyuki Ushio

  DOI：10.1021/jm00096a001

  日期：1992.9

  Synthesis and pharmacological evaluation of a series of 1,2-dihydro-1-[(5-methyl-1-imidazol-4-yl)methyl]-2-oxopyridine 5-HT3 antagonists are described. The key pharmacophoric elements were defined as a basic nitrogen, a group capable of hydrogen bonding interactions, and an aromatic moiety. 1,2-Dihydro-2-oxopyridine moiety could be a good linking group because of its nicely planar structure. The steric limitations of the aromatic moiety were investigated by X-ray analysis and computer analysis and shown to be optimal when the aromatic moiety was constrained within an arched planar system, which could be successfully replaced by 3-(2-thienyl)-2-oxopyridine function or 6-amino-7-chloro-1-isoquinolinone function without any loss of the activity. Among the synthesized compounds, 42 showed the most potent activity in the inhibition of Bezold-Jarisch reflex in rats. Compounds 44a and 64 were orally active in the protection against cisplatin-induced emesis in dogs or ferrets. Structure-activity relationships are discussed.